AEMD — Aethlon Medical, Inc.

Aethlon Medical (AEMD) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Balance: Approximately $5.8 million as of September 30, 2025.
• Operating Expenses: Consolidated operating expenses decreased to $1.5 million, down 48% from $2.9 million in Q2 2025.
  • Payroll and Related Expenses: Decreased by $778,000 due to lower headcount and reduced bonus accruals.
  • General and Administrative Expenses: Declined by $437,000, aided by a $218,000 R&D tax incentive credit from Australia.
  • Professional Fees: Decreased by $177,000, primarily due to reduced investor relations and contract labor expenses.
• Operating Loss: Reduced to $1.5 million from $2.8 million year-over-year.

2. Strategic Updates and Business Highlights

• Clinical Trials: Progress in the Australian oncology trial for the Hemopurifier, with successful completion of treatments in Cohort 1. No serious adverse events reported.
• Cohort 2 Initiatives: Aethlon is implementing a three-pronged strategy to accelerate participant enrollment, including virtual meetings with investigators, expanding trial sites, and engaging a marketing firm for patient outreach.
• Research and Development: Focus on Long COVID, with plans to publish preclinical data and explore the Hemopurifier's compatibility with simplified treatment systems.

3. Forward Guidance and Outlook

• Enrollment Expectations: Targeting one patient per month for Cohort 2, with the hope of completing the cohort by mid-2026. The company is actively working to enhance recruitment efforts.
• Future Data Releases: Anticipation of more comprehensive data from Cohort 2, which will help assess the efficacy of the Hemopurifier in reducing extracellular vesicles (EVs) and improving T cell responses.

4. Bad News, Challenges, or Points of Concern

• Patient Recruitment Challenges: Slow enrollment in the Australian trial due to the complexity of the treatment and the need for extensive patient education.
• Market Conditions: The potential impact of seasonal factors (e.g., summer holidays in Australia) on recruitment rates.
• Regulatory and Funding Risks: Limited interest in non-dilutive government funding opportunities unless they align closely with Aethlon's strategic goals.

5. Notable Q&A Insights

• Cohort 1 Follow-Up: No additional data on the clinical responses of Cohort 1 participants beyond the 8-week follow-up, as the trial is primarily focused on safety and feasibility.
• EV and T Cell Data: Directional changes observed in EV levels and T cell populations are promising, but further validation is needed with larger cohorts.
• Focus on Long COVID: Aethlon is committed to exploring the Hemopurifier's potential in various indications, including Long COVID, while prioritizing resources effectively.

Overall, Aethlon Medical is making strides in its clinical trials and cost management, although it faces challenges in patient recruitment and market conditions. The company remains focused on strategic initiatives to enhance its research and development efforts while navigating potential risks.